Skip to main content
Premium Trial:

Request an Annual Quote

Super Religare Signs Deal to Market Rosetta Genomics’ miRNA Diagnostics

Premium

Rosetta Genomics this week announced that it has licensed the exclusive distribution rights to its three microRNA-based diagnostics in India, Saudi Arabia, Qatar, and the United Arab Emirates to India’s Super Religare Laboratories.

Under the deal, Super Religare will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

Tissue samples will be sent from Super Religare’s territories to Rosetta’s Philadelphia-based laboratory for analysis. Additional terms of the arrangement were not disclosed.

News of the deal comes just days after Rosetta said it had licensed the diagnostics’ Canadian market rights to Warnex Medical Laboratories (see RNAi News, 8/13/2009).

In April, Rosetta signed a deal giving Prometheus Laboratories the US rights to the three tests (see RNAi News, 4/16/2009). In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.